Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Briefing
  • Published:

Phospholipid modifier PLAAT3 links defective PPARγ-dependent signaling to lipodystrophy

Whole-exome and genome sequencing in consanguineous families with unsolved lipodystrophy identified biallelic pathogenic loss-of-function variants in the phospholipase gene PLAAT3. Multi-omics and functional analyses in human and mouse PLAAT3-deficient adipose tissue and adipose stem cells revealed an adipocyte differentiation defect that is mediated by an altered gene network downstream of the adipogenesis master regulator PPARγ.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Loss of PLAAT3 leads to defective adipocyte differentiation.

References

  1. Mann, J. P. & Savage, D. B. What lipodystrophies teach us about the metabolic syndrome. J. Clin. Invest. 129, 4009–4021 (2019). A review that clearly explains the general interest of studying genetic lipodystrophies to understand the metabolic syndrome.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Jaworski, K. et al. AdPLA ablation increases lipolysis and prevents obesity induced by high-fat feeding or leptin deficiency. Nat. Med. 15, 159–169 (2009). This paper reports a Plaat3-knockout mouse that shows features of a lipodystrophy syndrome.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Qin, Q. et al. Lisa: inferring transcriptional regulators through integrative modeling of public chromatin accessibility and ChIP-seq data. Genome Biol. 21, 32 (2020). This paper describes a user-friendly bioinformatics tool to predict the transcriptional regulators of differentially expressed gene sets.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Ahmadian, M. et al. PPARγ signaling and metabolism: the good, the bad and the future. Nat. Med. 19, 557–566 (2013). A review that discusses the pros and cons of PPARγ agonists as potent insulin sensitizers in the treatment of type 2 diabetes.

    Article  CAS  PubMed  Google Scholar 

  5. Sobreira, N. et al. GeneMatcher: a matching tool for connecting investigators with an interest in the same gene. Hum. Mut. 36, 928–930 (2015). This paper describes a freely accessible web-based tool to identify additional individuals with rare phenotypes and variants in a gene of interest.

    Article  PubMed  Google Scholar 

Download references

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This is a summary of: Schuermans, N. et al. Loss of phospholipase PLAAT3 causes a mixed lipodystrophic and neurological syndrome due to impaired PPAR signaling. Nat. Genet. https://doi.org/10.1038/s41588-023-01535-3 (2023).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Phospholipid modifier PLAAT3 links defective PPARγ-dependent signaling to lipodystrophy. Nat Genet 55, 1790–1791 (2023). https://doi.org/10.1038/s41588-023-01536-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41588-023-01536-2

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing